Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has authorized 11 new Zyn Ultra nicotine pouch products, bringing the total number of FDA-authorized nicotine pouches to 43. The agency says the higher-strength pouches contain lower levels of harmful constituents than other tobacco products and may help adult smokers switch. Critics, however, warn that flavored products are already fueling youth nicotine use.
The FDA has authorized 11 new Zyn Ultra nicotine pouch products from Swedish Match USA, including flavors like Cool Mint, Menthol, Peppermint, and Wintergreen in 9 mg and 11 mg strengths. The agency says the products contain lower levels of harmful constituents than other oral and smokeless tobacco products and may deliver enough nicotine to reduce cravings and withdrawal symptoms, supporting behavioral change for adult smokers looking to switch.
This latest authorization is part of a broader FDA push that began in January 2025, when the agency first approved 20 Zyn products for sale. In June 2026, the FDA went further, allowing Zyn to carry a modified risk claim stating that switching from cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
By the Numbers:
Why it matters: The FDA's growing authorization of flavored nicotine pouches reflects a harm-reduction strategy aimed at adult smokers — but public health advocates warn the flavored products risk driving youth nicotine addiction, a tension that will likely shape future regulatory decisions.
